Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation.

The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. 

Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK. 


Eli Lilly

Longwood Fund

Sofinnova Partners

SV Health Investors

Oxford Science Enterprises

Sitryx

Sitryx is a biopharmaceutical company focused on developing disease-modifying therapeutics in immuno-oncology and immunoinflammation. The company leverages its proprietary science and technology platform to identify and modulate novel targets in the regulation of immune cell metabolism.

COM:SITRYX

Sitryx

Filings Not Available